drugset
drugset / Trial / NCT05434585

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

NCT05434585 ↗

Phase 1 Unknown 60 enrolled Suzhou Abogen Biosciences Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection. this study is conducted during Indonesian subjects aged 18 years and older who have not received SARS-CoV-2 vaccines.

Timeline

Start
2022-07-08
Primary completion
2022-10-10
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ABO-CoV.617.2 Unknown 15 ug Intramuscular
Subject ABO1009-DP Messenger RNA (mRNA) 15 ug Intramuscular

Indications

COVID-19